October 18, 2018 – By Darrin Black

Analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD) to report $-0.63 EPS on November, 14.They anticipate $0.09 EPS change or 12.50 % from last quarter’s $-0.72 EPS. After having $-0.65 EPS previously, Clearside Biomedical, Inc.’s analysts see -3.08 % EPS growth. The stock decreased 6.85% or $0.4 during the last trading session, reaching $5.44. About 417,969 shares traded or 67.82% up from the average. Clearside Biomedical, Inc. (NASDAQ:CLSD) has declined 18.80% since October 18, 2017 and is downtrending. It has underperformed by 34.42% the S&P500.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. The company has market cap of $174.21 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). It currently has negative earnings. The company’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

More recent Clearside Biomedical, Inc. (NASDAQ:CLSD) news were published by: Globenewswire.com which released: “Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors” on September 26, 2018. Also Investingnews.com published the news titled: “Pharmaceutical Update: Q3 2018 in Review” on October 16, 2018. Nasdaq.com‘s news article titled: “Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, LB Foster, Merrimack …” with publication date: October 16, 2018 was also an interesting one.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Chart

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

By



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *